The Classic Egg-Yolk Macular Dystrophy of Childhood
A mango doesn't turn from hard and green to ripe and golden overnight — it moves through a recognisable sequence of stages, each one a distinct, fairly predictable point along a longer process rather than a sudden jump. Best disease behaves in a comparable way beneath the macula: a rounded, golden-yellow deposit starts out as a smooth, intact shape, gradually breaks apart over a period of years, and eventually settles into its final form. Vitelliform, a name borrowed from the Latin word for egg yolk, refers to nothing more than the deposit's early appearance — and it's this entire gradual sequence, rather than any single symptom, that determines how the condition gets tracked over time.
Something that often catches Pakistani families off guard at the first appointment: a child's lesion can look striking on examination — egg-yolk shaped and unmistakable — while reading remains completely comfortable for their age. How dramatic a lesion appears and how well a person actually sees aren't necessarily connected, which is exactly why getting the staging right matters more than reacting to an alarming-looking retinal photograph.
In the first stage, before the lesion has broken apart, sight generally stays close to normal — a child can carry an unmistakable finding on the retina and still see perfectly well. Trouble tends to begin once that smooth deposit fractures, something specialists often compare to a cracked egg; reading grows harder, and central vision turns blurred or slightly warped from around this point. Later stages usually settle into whatever vision loss has already occurred rather than continuing to worsen steadily, though a small proportion of patients experience one further, sudden drop if stray new blood vessels form beneath the retina.
BEST1 is the gene responsible. Working correctly, it produces bestrophin-1, a protein that regulates how ions and fluid move across the retinal pigment epithelium. When that process breaks down, fluid and pigment collect in the wrong place beneath the macula, gradually forming the visible lesion. Passed on as a dominant trait, it doesn't behave consistently from person to person — one relative might carry an obvious lesion and notice nothing at all, while another with the exact same mutation ends up with genuine, measurable vision loss.
The electro-oculogram usually provides the clearest answer, since it reliably comes back abnormal — showing a low Arden ratio — even when a standard ERG from the same eye reads as entirely normal. That gap between the two results is exactly what steers a specialist toward Best disease rather than a condition that merely resembles it. Tracking the lesion through repeat OCT scans across several visits shows how it's genuinely progressing, and a positive BEST1 test both confirms the diagnosis and flags relatives who might be silently carrying the same fault.
Since this lesion is fully capable of remaining unchanged for years at a stretch, specialists generally favour careful observation over rushing into treatment, all while watching for the modest chance of abnormal vessel growth as things slowly evolve. Regenerative stem cell therapy only enters the conversation once vision genuinely starts to slip, aimed at preserving whatever central vision is still functioning.
Indeed, and this is actually a familiar, reassuring pattern in the early stage of Best disease. The size of a lesion on a photograph tells us remarkably little about actual visual function, which is exactly why careful staging matters far more than a dramatic-looking image.
No — it stays entirely local and benign, confined to the retina, with no connection whatsoever to cancer. It does move through a well-documented sequence of stages over time, and tracking that exact sequence is the entire reason behind our continued monitoring.
It comes down to variable expressivity, a trait BEST1 mutations are well known for producing. He could easily carry the identical faulty gene without it ever producing a visible lesion or any symptoms — testing him directly is the only way to know for certain rather than assuming he's simply been spared.
No, certainly not for everyone — a good number of patients keep solid central vision for years on end, especially when the lesion stalls at an earlier stage. Because the trajectory genuinely varies between individuals, staying on top of monitoring is what lets us act quickly the moment something actually changes.